However, there is a large group of patients with clinically advanced CRC whose tumors are resistant to anti-PD-1/PDL1 therapy, especially the patients with microsatellite-stable (MSS) tumors or with low microsatellite instability (MSI-L) [16]. This evidence concerns the gene CD274 and colorectal carcinoma.